---
document_datetime: 2025-02-18 16:34:16
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ravicti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ravicti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.4188117
conversion_datetime: 2025-12-18 21:32:08.889416
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## RAVICTI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0049/G            | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.2.c.2 - Change to importer, batch release | 17/02/2025                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products   |            |            |      |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/10454 /202401 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                                                                                                           | 03/10/2024 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0047             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                       | 13/02/2024 | 23/01/2025 | SmPC |                                   |
| IA/0046/G           | This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                            | 24/07/2023 | n/a        |      |                                   |
| IA/0045             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                             | 10/02/2023 | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

|           | supplier of the AS, starting material, reagent or used in the manufacture of the AS or of a novel excipient                                                                                                                                                                                                                                                                                                                 |            |            |                        | or intermediate manufacturer   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| II/0044   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                               | 09/02/2023 | n/a        |                        |                                |
| IAIN/0043 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                  | 19/10/2022 | 04/10/2023 | SmPC, Labelling and PL |                                |
| IB/0040/G | This was an application for a group of variations. B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 09/03/2022 | n/a        |                        |                                |
| IA/0042/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                | 08/02/2022 | n/a        |                        |                                |
| IB/0041   | B.II.d.1.z - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                         | 07/02/2022 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                       |                                                                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0038/G | This was an application for a group of variations. Group of variations consisting of: - Submission of the final study report, HPN-100-014 non-interventional registry study 'Long-Term Registry of Patients with Urea Cycle Disorders (UCDs) conducted in the US'. - An update to the RMP (version 7.3) submitted and agreed to remove the important potential risk of carcinogenicity. The update to the RMP is based on the review of new and available data including the study report for HPN-100-014 and a new toxicological expert examination of pre-clinical carcinogenicity findings as well as a cumulative review of literature and post marketing data. In accordance with the proposed changes to the RMP, the requested waiving of the Annex II imposed condition related to the non-interventional post authorisation safety study (PASS), 'European Post- Authorization Registry for RAVICTIÂ® (glycerol phenylbutyrate) Oral Liquid in Partnership with the European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD)' is agreed but this PASS agreed to be discontinued is retained in the RMP as a category 3 PASS until final PASS results submission. The SmPC and Package Leaflet have been updated to delete the information on additional monitoring (including the black triangle). | 16/12/2021 | 05/05/2022 | SmPC, Annex II and PL | Following submission of new data, the CHMP agreed that the uncertainties to be evaluated in the imposed non- interventional post-authorisation safety study (PASS) for Ravicti have been adequately addressed. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                       |            |            |                                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10454 /202101 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/09/2021 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0037/G           | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site A.7 - Administrative change - Deletion of manufacturing sites | 28/04/2021 | 05/05/2022 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0036/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation   | 13/01/2021   | n/a        |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10454 /202001 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                   | 03/09/2020   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| R/0034              | Renewal of the marketing authorisation.                                                                                                                                                                                                 | 25/06/2020   | 25/08/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of RAVICTI in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0033           | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                   | 17/12/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IB/0028             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                           | 20/09/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IAIN/0032/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a                                                                              | 18/09/2019   | 25/08/2020 | Annex II and PL                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                      |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10454 /201901 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/09/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0031             | B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)                                                                                                                                                                                                                                                                                                                                                                                                            | 21/08/2019 | 25/08/2020 | SmPC, Labelling and PL |                                   |
| IB/0030             | B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms                                                                                                                                                                                                                                                                                                                         | 19/08/2019 | n/a        |                        |                                   |
| IA/0029/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 28/06/2019 | n/a        |                        |                                   |
| T/0026              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 03/05/2019 | 06/06/2019 | SmPC,                  |                                   |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            | Labelling and PL   |                                                                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------------------------------------|
| IAIN/0025/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging -                                  | 03/05/2019 | 06/06/2019 | Annex II and PL    |                                                                 |
| II/0024     | B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions                                                                                                                                                                                                                                                                            | 31/01/2019 | n/a        |                    |                                                                 |
| II/0019     | Extension of indication to include in the authorised indication the new paediatric population from 0 to 2 months for RAVICTI based on the final results from study HPN-100-009, an Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects under Two Years of Age with Urea Cycle Disorders (UCDs); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. | 15/11/2018 | 18/12/2018 | SmPC and PL        | Please refer to Scientific Discussion 'Ravicti-H-C-3822-II- 19' |

<div style=\"page-break-after: always\"></div>

|                     | Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023             | Update of section 5.1 of the SmPC in order to update the efficacy and safety information based on study HPN-100-011, a non randomised, open-label safety extension study on the long term use of HPN- 100 in Urea Cycle Disorders. In addition, QRD changes are made in the labelling related to the addition of section 17 and 18 and in line with the QRD template version 10.0 C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 18/10/2018 | 18/12/2018 | SmPC and Labelling | An open-label, long-term study (Study 5) was conducted to assess ammonia control in paediatric patients with UCD. The study enrolled a total of 45 paediatric patients between the ages of 1 and 17 years with UCD who had completed Study 2 and the safety extensions of Studies 3 and 4. The length of study participation ranged from 0.2 to 5.9 years. Venous ammonia levels were monitored at a minimum of every 6 months. Mean venous ammonia values in paediatric patients in Study 5 were within normal limits during long-term (24 months) treatment with glycerol phenylbutyrate (range: 15-25 micromol/L). Of the 45 paediatric patients participating in the open-label treatment with glycerol phenylbutyrate, 11 patients (24%) reported a total of 22 hyperammonemic crises. |
| PSUSA/10454 /201711 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/06/2018 | n/a        |                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0021             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/05/2018 | 18/12/2018 | SmPC and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0020/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                    | 11/04/2018 | n/a        |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                   |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0017             | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)                                                                                                                                                                                                                                                                                                                       | 27/02/2018 | 12/04/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10454 /201705 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                                                                                          | 11/01/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0016             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                    | 19/10/2017 | n/a        |                        |                                   |
| IA/0015/G           | This was an application for a group of variations. A.z - Administrative change - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 11/09/2017 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                |            |            |                 |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0013             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                 | 15/08/2017 | n/a        |                 |                                   |
| IB/0012/G           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products | 20/06/2017 | n/a        |                 |                                   |
| PSUSA/10454 /201611 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                         | 09/06/2017 | n/a        |                 | PRAC Recommendation - maintenance |
| N/0011              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                              | 08/05/2017 | 12/04/2018 | Labelling       |                                   |
| IAIN/0010/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                               | 03/05/2017 | 12/04/2018 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |            |                  |                                                                                                                                                                           |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0009              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/03/2017 | 12/04/2018 | Labelling and PL |                                                                                                                                                                           |
| PSUSA/10454 /201605 | Periodic Safety Update EU Single assessment - glycerol phenylbutyrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/01/2017 | n/a        |                  | PRAC Recommendation - maintenance                                                                                                                                         |
| IB/0007             | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/01/2017 | 16/02/2017 | SmPC             |                                                                                                                                                                           |
| II/0004             | Update of SmPC section 4.5 based on the final clinical study report for the Drug/Drug Interaction study HPN-100-027.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/05/2016 | 16/02/2017 | SmPC             | The effects of glycerol phenylbutyrate on cytochrome P450 (CYP) 2C9 isoenzyme and potential for interaction with celecoxib has been studied in humans with no evidence of |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                      |            |            |                                  | an interaction observed.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------|
| IB/0005   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 31/03/2016 | n/a        |                                  |                            |
| IB/0003   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                         | 21/03/2016 | 16/02/2017 | SmPC, Annex II, Labelling and PL |                            |
| IAIN/0002 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                     | 01/03/2016 | n/a        |                                  |                            |
| T/0001    | Transfer of Marketing Authorisation                                                                                                    | 04/02/2016 | 24/02/2016 | SmPC, Labelling and PL           |                            |